Aernoud Fiolet

203 The efficacy and safety of low-dose colchicine in patients with coronary disease 14 Supplementary Appendix Supplementary Figure S3B: Subgroup meta-analysis of females versus males in colchicine trials for the primary and secondary composite end points Composite of myocardial infarction, stroke, or cardiovascular death Composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death Supplementary Figure S3B: Subgroup meta-analysis of females versus males in colchicine trials for the primary and secondary composite end points Subgroup analyses of females vs. males and the pooled relative risks for the composite of myocardial infarction, stroke, or cardiovascular death (upper panel) or the composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death (lower panel) in patients treated with colchicine as compared to placebo or no colchicine. Abbreviations: CI, confidence interval. GIV, generic inverse variance.